QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=A619E267BCB13362939393AACC1814CF;jsessionid=637D4A507FB092A4C6EF2E7FEC025755;jsessionid=6E7C5D478AC783D384DD4A3A3EF9D0E4;jsessionid=4F53475AB40C1355C4F24BED1C143391;jsessionid=A53B0E6DF04E94160FEA15FDC2792DC6;jsessionid=168C2944E96E65ACE2523940D3F2F180;jsessionid=5C71873297092B1011AB073103A497F3;jsessionid=2EA2B90C124DAC1647C55002E24A2BB3 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=A619E267BCB13362939393AACC1814CF;jsessionid=637D4A507FB092A4C6EF2E7FEC025755;jsessionid=6E7C5D478AC783D384DD4A3A3EF9D0E4;jsessionid=4F53475AB40C1355C4F24BED1C143391;jsessionid=A53B0E6DF04E94160FEA15FDC2792DC6;jsessionid=168C2944E96E65ACE2523940D3F2F180;jsessionid=5C71873297092B1011AB073103A497F3;jsessionid=2EA2B90C124DAC1647C55002E24A2BB3